Green Spring SARS-CoV-2 Antigen Rapid Test Kit

Green Spring SARS-CoV-2 Antigen Rapid Test Kit

The Green Spring SARS-CoV-2 antigen rapid rapid test (colloidal gold) can be used widely and enables a corona infection to be detected quickly and easily in 4 different sampling methods. The smear can either be taken from the pharynx (oropharyngeal smear),  the front of  the nose (anterior nasal smear) and the nasopharynx (nasopharyngeal smear) by trained specialists, or by a “lollitest” as a saliva sample .

This means that the needs of the patient can be individually addressed without having to have various COVID-19 tests in stock. With the pre-filled extraction tubes, the test is quickly ready for use. The test result is available within 15 to 20 minutes.

product details
4 in 1 rapid antigen test: Lolli test, nose swab, throat swab or nose/throat swab possible
Sample material: saliva, nose, nose/throat or throat sample
Lateral flow immunoassay for the qualitative detection of nucleocapsid protein antigen of SARS-CoV-2
Fast test results in approx. 15 minutes
Reliably detects all virus mutations, including omicron (B.1.1.529) and omicron sublines (BA.4 and BA.6)
Easy to use
Reimbursable under the Test regulation
On the list of the European Commission for COVID-19 rapid antigen tests (EU-wide recognized)
Confirmed overall sensitivity: 86% (Paul-Ehrlich-Institut)
No. 1 in sensitivity:
100% specificity
98% sensitivity
Please also note the instructions for use!
PEI confirms: Green Spring SARS-CoV-2 Antigen Rapid Test Kit in 1st place
In a study conducted by the Paul Ehrlich Institute in May 2021, the Green Spring test achieved the highest detection values ​​in all categories based on overall specificity. In a comparative evaluation of 122 BfarM-listed antigen tests, Green Spring Antigen Test emerged as the best test on the market.

Information for service providers
Billing: Before placing your order, please inquire at your Association of Statutory Health Insurance Physicians (KV) about their specifications, as these may vary from region to region. With the entry into force of the new coronavirus test ordinance on June 30, 2022, the health insurance benefit for carrying out rapid antigen tests includes material costs of a maximum of €2.50 and treatment costs of a maximum of €7 per test. If the person to be tested does not meet the requirements for a free rapid antigen test, a personal contribution of €3 will be charged, which reduces the flat-rate treatment fee to a maximum of €4. Unrelated tests can be billed as an IGEL service. This rapid antigen test is on the European Commission’s list of rapid antigen tests for COVID-19.


Leave a Reply

Your email address will not be published.